Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
The govt has rolled out three schemes for promoting the manufacture of API
It works as an adjunct to standard care based on robust clinical trials
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Price band in the range of Rs 933 to Rs 954
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Subscribe To Our Newsletter & Stay Updated
